ClinicalTrials.gg

Program

darovasertib

Also written as “Darovasertib”, “IDE196” and “LXS196”.

Its studies are mostly in Uveal Melanoma, led by 2 companies.

Furthest: phase 3, since Jul 12, 20236 company-led studies, 5 open or runningNext primary completion: Jan 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
IDEAYA Biosciences55 open or runningphase 3since Jul 12, 2023May 9, 2019Jan 15, 2027phase 3 · NCT05987332
Novartis10 open or runningphase 1since Nov 6, 2015Nov 6, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2015First study: phase 1 study in Uveal MelanomaNew to NovartisNovartis · NCT02601378 · 107 enrolled · United States, Australia, France and more
  2. May 9, 2019IDEAYA Biosciences's first study: phase 2 study in Uveal MelanomaNew to IDEAYA BiosciencesIDEAYA Biosciences · NCT03947385 · 336 planned · United States, Australia, Canada
  3. Jun 6, 2023Phase 2 study in Uveal MelanomaIDEAYA Biosciences · NCT05907954 · 160 enrolled · United States, Australia, Canada and more
  4. Jul 12, 2023Phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT05987332 · 420 enrolled · United States, Australia, Belgium and more
  5. Jun 3, 2025Phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07015190 · 520 planned · United States, Australia, Austria and more
  6. Aug 21, 2026Phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07804186 · 450 planned · United States, Australia, Canada and more

Ahead

  1. Jan 15, 2027Primary completion: phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT05987332
  2. Jan 29, 2027Primary completion: phase 2 study in Uveal MelanomaIDEAYA Biosciences · NCT03947385
  3. Apr 30, 2027Primary completion: phase 2 study in Uveal MelanomaIDEAYA Biosciences · NCT05907954
  4. Oct 2030Primary completion: phase 3 study in Uveal MelanomaIDEAYA Biosciences · NCT07015190

TargetBeta

PRRT2 →read by rule
“An orally available protein kinase C (PKC) inhibitor ”NCIt, by rule

Other programs on PRRT2

ProgramCompanyFurthest phaseStudies
PKC-beta Inhibitor MS-553rulemingsight-pharmaceuticals-incphase 26

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07804186Uveal Melanoma · United States, Australia, Canada and more3RecruitingIDEAYA BiosciencesMar 2034450
NCT07015190Uveal Melanoma · United States, Australia, Austria and more3RecruitingIDEAYA BiosciencesOct 2030520
NCT05987332Uveal Melanoma · United States, Australia, Belgium and more3Active, not recruitingIDEAYA BiosciencesJan 15, 2027420
NCT05907954Uveal Melanoma · United States, Australia, Canada and more2Active, not recruitingIDEAYA BiosciencesApr 30, 2027160
NCT03947385Uveal Melanoma · United States, Australia, Canada2RecruitingIDEAYA BiosciencesJan 29, 2027336
NCT02601378Uveal Melanoma · United States, Australia, France and more1TerminatedNovartisJan 7, 2022107

How it is read

Names in the registry

  • “Darovasertib”, 3 entries
  • “IDE196”, 2 entries
  • “LXS196”, 1 entry
  • “LXS196 and HDM201”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.